Ongoing Glomerular Clinical Trials

Diabetic nephropathy (DN), FSGS and MCD 

TRPC5 inhibitor GFB-887 for DN, FSGS or MCD                                                                  (JR/IO)

[ ClinicalTrials.gov ] [ Study Website ] [ Contact Research Coordinator: io67@cumc.columbia.edu ]

 

IgA nephropathy  

Iptacopan (LNP023) for IgA Nephropathy (APPLAUSE) version 01                   (PAC/AP)

[ ClinicalTrials.gov ] [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]

 

C3 Glomerulopathy and MPGN

PEGCETACOPLAN for Recurrent C3G or IC-MPGN (NOBLE)                                            (ASB/IO)

[ ClinicalTrials.gov ] [ Study Website [ Contact Research Coordinator: io67@cumc.columbia.edu ]  

 

Iptacopan (LNP023) for C3 Glomerulopathy (APPEAR-C3G) version 0                         (ASB/IO)

[ ClinicalTrials.gov ] [ Contact Research Coordinator: io67@cumc.columbia.edu ]

 

 Membranous Nephropathy

Belimumab with Rituximab for Primary MN (REBOOT)                                                     (ASB/AP)

[ ClinicalTrials.gov ] [ Study Website [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]

 

Obinutuzumab for Primary MN (MAJESTY)                                                                         (ASB/AP)

[ ClinicalTrials.gov ] [ Study Website [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]

 

Lupus Nephritis and SLE  

EQ001 (itolizumab, anti-CD6 IgG1 k) for SLE (EQUALISE)                                                 (WA/AP)

[ ClinicalTrials.gov ] [ Study Website ]  [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]

 

Obinutuzumab for LN (REGENCY)                                                                                              (GBA/AP)

ClinicalTrials.gov ] [ Study Website ]  [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]

 

Fibrillary Glomerulopathy  

ACTH for Fibrillary glomerulopathy (FACT)                                                                         (GBA/IO)

[ ClinicalTrials.gov ]  [ Contact Research Coordinator: io67@cumc.columbia.edu ] 

 

Alport Syndrome

Lademisiren (SAR339375) for Alport Syndrome (HERA) v3.0                                         (GA/AP)

[ ClinicalTrials.gov ] [ Study Website [ Contact Research Coordinator: arp2209@cumc.columbia.edu ]